Gensight Biologics S.a annual operating cash flow
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Operating Cash Flow Growth & History (SIGHT)
Gensight Biologics S.a's operating cash flow was −€9.2M for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −€9.2M | €3.8M | — |
| 2024 | 2024-12-31 | −€12.9M | €11.7M | — |
| 2023 | 2023-12-31 | −€24.7M | €9.1M | — |
| 2022 | 2022-12-31 | −€33.8M | −€16.6M | — |
| 2021 | 2021-12-31 | −€17.1M | −€2.1M | — |
| 2020 | 2020-12-31 | −€15.0M | — | — |
Gensight Biologics S.a operating cash flow trends
Over the last five fiscal years, Gensight Biologics S.a's operating cash flow increased from −€15.0M to −€9.2M, a change of €5.9M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company official filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...